The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares in continental Europe where the Company is conducting its R&D activities in France and Switzerland. In addition to AIM, this dual listing on Euronext allows ImmuPharma to join the number one European stock exchange for Life Sciences and the world's...
RNS Number: 5515 W Immupharma PLC 11 December 2019 11 December 2019. ImmuPharma PLC, a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme,...
RNS Number: 3985 V Immupharma PLC 03 December 2019 RNS REACH 3 December 2019. IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO. ImmuPharma PLC, a specialist drug discovery and development company, is pleased to announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13-15 January 2020, at the Hilton, San Francisco...
RNS Number: 2427 V Immupharma PLC 02 December 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9181 U Immupharma PLC 28 November 2019. ImmuPharma PLC, a specialist drug discovery and development company, announces a licence and development agreement with Avion Pharmaceuticals LLC, for the exclusive rights to Lupuzor™ in North America. ·Avion and ImmuPharma will co-develop Lupuzor™ to allow registration for marketing in the US, Europe and...
RNS Number: 5939 U Immupharma PLC 25 November 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5919 U Immupharma PLC 25 November 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3740 S Immupharma PLC 05 November 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3723 S Immupharma PLC 05 November 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0103 P Immupharma PLC 07 October 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0095 P Immupharma PLC 07 October 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8461 O Immupharma PLC 04 October 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8440 O Immupharma PLC 04 October 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4085 O Immupharma PLC 01 October 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4068 O Immupharma PLC 01 October 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
ImmuPharma Plc
IMM.L
ImmuPharma Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    167.39M

Featured Media

Company Profile

ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need Low marketing costs Relatively low development costs Founded first in Basel, Switzerland in 1999 and led by an experienced management team, ImmuPharma now has important R&D collaboration arrangements with highly respected health and medical research laboratories in Europe. The company plans either to bring its drug candidates to market itself, or to license them in corporate deals to other pharmaceutical companies.

Classification

Market Indices-

Locations

HQ
50 Broadway
Westminster
London
SW1 H0RG
Watchlist